Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent

By D. Boocock, G. Faust, K. Patel, A. Schinas, V. Brown, M. Ducharme, T. Booth, J. Crowell, M. Perloff, A. Gescher and 2 more. Cancer Epidemiology, Biomarkers and Prevention, 2007

838 citations recorded by the source corpus.

Subfields: Geriatrics and Gerontology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/5fcdc252fc2de647ec3298a05ba7c05964589176

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. I. Kapetanovic
2. V. Brown
3. M. Muzzio
4. K. Patel
5. M. Viskaduraki
6. Zhihua Huang
7. T. Thompson
8. J. Crowell

Citations in the corpus

• Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics and Effect on the Insulin-like Growth Factor Axis (2010, positive): “Reports on trials of resveratrol in humans after single (8,9) or multiple daily doses of up to 600 mg per day administered over two or three days (10,11) suggest that it is safe under the tested conditions.”
• Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases (2013, neutral): “Gastric absorption explains the peak of free resveratrol in the plasma 30 min after ingestion (8, 39, 475, 479).”
• Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats (2010, background): “of resveratrol can generate plasma levels of parent drug that are necessary to achieve the chemopreventive and other desirable activities that have been reported in experimental model systems [6].”